NASDAQ:ENTX - Entera Bio Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.00
  • Forecasted Upside: 155.81 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$4.30
▼ -0.07 (-1.60%)

This chart shows the closing price for ENTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Entera Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ENTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ENTX

Analyst Price Target is $11.00
▲ +155.81% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Entera Bio in the last 3 months. The average price target is $11.00, with a high forecast of $12.00 and a low forecast of $10.00. The average price target represents a 155.81% upside from the last price of $4.30.

This chart shows the closing price for ENTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Entera Bio. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/20/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/18/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/7/2021B. RileyLower Price TargetBuy$14.00 ➝ $11.00Low
7/12/2021AegisReiterated RatingBuy$12.00Low
6/24/2021B. RileyBoost Price TargetBuy$9.00 ➝ $14.00Low
6/16/2021B. RileyInitiated CoverageBuy$9.00High
3/22/2021AegisInitiated CoverageBuy$12.00Medium
3/11/2021Maxim GroupBoost Price TargetBuy$5.00 ➝ $10.00High
7/24/2020Maxim GroupReiterated RatingBuyLow
9/24/2019Maxim GroupSet Price TargetBuy$8.00Low
8/20/2019Maxim GroupSet Price TargetBuy$8.00Low
7/31/2019Maxim GroupSet Price TargetBuy$8.00N/A
7/2/2019Maxim GroupInitiated CoverageBuy$12.00Low
3/28/2019Maxim GroupSet Price TargetBuy$12.00Low
1/31/2019Maxim GroupReiterated RatingBuy$12.00Low
12/11/2018Maxim GroupReiterated RatingBuy$12.00High
8/21/2018Maxim GroupReiterated RatingBuy$12.00Low
8/3/2018Maxim GroupInitiated CoverageBuy$12.00High
(Data available from 10/19/2016 forward)

News Sentiment Rating

0.45 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/21/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/21/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/20/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/19/2021
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/19/2021

Current Sentiment

  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Entera Bio logo
Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of orally delivered large molecule therapeutics. It develops an oral formulation of parathyroid hormone. The company was founded on June 1, 2010 and is headquartered in Jerusalem, Israel.
Read More

Today's Range

Now: $4.30
Low: $4.26
High: $4.33

50 Day Range

MA: $4.83
Low: $4.37
High: $5.72

52 Week Range

Now: $4.30
Low: $1.01
High: $10.16

Volume

600 shs

Average Volume

3,785,425 shs

Market Capitalization

$101.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.64

Frequently Asked Questions

What sell-side analysts currently cover shares of Entera Bio?

The following sell-side analysts have issued research reports on Entera Bio in the last twelve months: Aegis, B. Riley, Maxim Group, and Zacks Investment Research.
View the latest analyst ratings for ENTX.

What is the current price target for Entera Bio?

3 Wall Street analysts have set twelve-month price targets for Entera Bio in the last year. Their average twelve-month price target is $11.00, suggesting a possible upside of 155.8%. Aegis has the highest price target set, predicting ENTX will reach $12.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $10.00 for Entera Bio in the next year.
View the latest price targets for ENTX.

What is the current consensus analyst rating for Entera Bio?

Entera Bio currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ENTX will outperform the market and that investors should add to their positions of Entera Bio.
View the latest ratings for ENTX.

How do I contact Entera Bio's investor relations team?

Entera Bio's physical mailing address is FIFTH FLOOR KIRYAT HADASSAH MINRAV BUILDING, JERUSALEM L3, 9112002. The company's listed phone number is (722) 532-7151 and its investor relations email address is [email protected] The official website for Entera Bio is www.enterabio.com.